Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era

Study acronym: SHAPE-PSMA
StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Aug 8, 2026 → Aug 8, 2028
See other at-risk trials from University Health Network, Toronto

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Aug 8, 2026 to Aug 8, 2028
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 1 of 3 entries
    • Study description revised
  2. Re-verified, no change to tracked fieldsv4
  3. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Mar 1, 2026 to Aug 8, 2026
    • Start date changed from estimate of Aug 2024 to Aug 8, 2024
    • Eligibility criteria expanded, about 2 words
  4. Start date: Jul 2024 to Aug 2024
    • Secondary endpoints: details revised at 2 of 3 entries
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an interventional, single-centre, single-arm, non-randomized, prospective, feasibility trial investigating salvage MR-guided High-Dose-Rate brachytherapy for prostate bed recurrence after postoperative radiotherapy.
Trial Details
NCT Number NCT06508567
Lead Sponsor University Health Network, Toronto
Conditions
(from sponsor)		 Prostate Cancer Recurrent, Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov